Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sangamo Biosciences ( (SGMO) ) has provided an update.
On May 12, 2025, Sangamo Therapeutics announced an underwriting agreement with Cantor Fitzgerald & Co. for the issuance and sale of shares and warrants, aiming to raise approximately $23 million. This offering, expected to close on May 14, 2025, is part of Sangamo’s strategy to bolster its financial position, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (SGMO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.
Spark’s Take on SGMO Stock
According to Spark, TipRanks’ AI Analyst, SGMO is a Neutral.
Sangamo Biosciences presents a challenging outlook with significant financial instability and operational risks. Declining revenues, negative cash flows, and a bearish technical trend weigh heavily on its score. While strategic partnerships and pipeline advancements offer some hope, the company’s immediate financial challenges, including the risk of delisting, necessitate urgent strategic actions to improve its financial health and market standing.
To see Spark’s full report on SGMO stock, click here.
More about Sangamo Biosciences
Sangamo Therapeutics, Inc. operates in the biotechnology industry, focusing on genomic therapies. The company specializes in developing treatments for genetic diseases using its proprietary gene-editing technology.
Average Trading Volume: 6,784,841
Technical Sentiment Signal: Sell
Current Market Cap: $171.2M
See more insights into SGMO stock on TipRanks’ Stock Analysis page.